Australia markets closed

Apellis Pharmaceuticals, Inc. (APLS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
41.70-1.98 (-4.53%)
At close: 04:00PM EST
41.70 0.00 (0.00%)
After hours: 06:03PM EST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2020
31/12/2019
31/12/2018
31/12/2017
Total revenue
256,273
250,646
0
0
0
Cost of revenue
25,199
25,050
-
-
-
Gross profit
231,074
225,596
-
-
-
Operating expenses
Research development
368,025
299,921
220,969
105,286
40,304
Selling general and administrative
179,801
139,401
67,046
22,639
10,463
Total operating expenses
547,826
439,322
288,015
127,925
50,767
Operating income or loss
-316,752
-213,726
-288,015
-127,925
-50,767
Interest expense
19,833
29,937
5,285
2,513
-
Total other income/expenses net
-182,301
-103,530
-16,516
-25.249
-142.15
Income before tax
-518,311
-343,029
-304,707
-127,502
-51,006
Income tax expense
-
1,845
-
-
-
Income from continuing operations
-520,156
-344,874
-304,707
-127,502
-51,006
Net income
-520,156
-344,874
-304,707
-127,502
-51,006
Net income available to common shareholders
-520,156
-344,874
-304,707
-127,502
-51,006
Basic EPS
-
-4.59
-4.90
-2.34
-3.68
Diluted EPS
-
-4.59
-4.90
-2.34
-3.68
Basic average shares
-
75,163
62,229
54,396
13,871
Diluted average shares
-
75,163
62,229
54,396
13,871
EBITDA
-
-312,455
-299,182
-124,989
-50,755